Glabridin inhibits urothelial bladder carcinoma cell growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest

Zhao Yang,Ying Bi,Wenkai Xu,Rui Guo,Mingxuan Hao,Youfeng Liang,Zongyi Shen,Liqi Yin,Changyuan Yu,Shihui Wang,Jiansong Wang,Jinmei Li,Jinku Zhang,Runfen Cheng,Qiongli Zhai,Haifeng Wang
DOI: https://doi.org/10.1111/cbdd.14147
2022-09-17
Abstract:This study revealed the effect of Glabridin on UBC in vivo and in vitro for the first time. CCK8 results showed that the IC50 values of BIU‐87 and EJ cells were 6.02 μg/ml and 4.36 μg/ml, respectivelyafter treatment with GLA for 48 h, which were significantly lower than liver cancer and oral cancer. Moreover, GLA induced apoptosis and cell cycle arrested at the G2 phase, inhibited the migration of UBC cells. Finally, GLA significantly inhibited tumor growth and prolonged the survival of tumor‐bearing mice in vivo. Glabridin (GLA) has a variety of biological activities and therapeutic effects in cancers. Whereas the effect of GLA on urothelial bladder carcinoma (UBC) cells and its underlying mechanisms remain unknown. The study revealed the effect of GLA on UBC and the potential mechanism of inducing cell apoptosis in vivo and in vitro. After treated with different concentrations of GLA, the cell activity decreased in a time‐ and dose‐dependent manner. The IC50 values of BIU‐87 and EJ cells at 48 h were 6.02 μg/ml and 4.36 μg/ml, respectively. Additionally, GLA induced apoptosis and cycle arrest of BIU‐87 and EJ cells in G2 phase. Furthermore, wound healing experiments showed that GLA significantly reduced the migration activities of BIU‐87 and EJ cells. Mechanically, GLA obviously increased the expression of BIM, BAK1, CYCS in both mRNA and protein levels, which led to the activation of the endogenous apoptotic pathway. Finally, GLA remarkably inhibited the growth of UBC tumors in vivo. In summary, GLA inhibited UBC cells growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest, highlighting that GLA could be utilized as a component to design a novel anti‐UBC drug.
What problem does this paper attempt to address?